Setanaxib

Setanaxib (GKT137831) is a selective NADPH oxidase (NOX1/4) inhibitor with Kis of 140 and 110 nM, respectively.

Product Specifications

CAS Number

[1218942-37-0]

Product Name Alternative

GKT137831; GKT831

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Ferroptosis; NADPH Oxidase

Type

Reference compound

Related Pathways

Apoptosis; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/GKT137831.html

Purity

99.81

Solubility

DMSO : 125 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=C1N(C2=CC=CC=C2Cl)NC(C1=C(C3=CC=CC(N(C)C)=C3)N4C)=CC4=O

Molecular Formula

C21H19ClN4O2

Molecular Weight

394.85

Precautions

H302, H315, H319, H335

References & Citations

[1]Aoyama T, et al. Nicotinamide adenine dinucleotide phosphate oxidase in experimental liver fibrosis: GKT137831 as a novel potential therapeutic agent. Hepatology. 2012 Dec;56 (6) :2316-27.|[2]Green DE, et al. The Nox4 inhibitor GKT137831 attenuates hypoxia-induced pulmonary vascular cell proliferation. Am J Respir Cell Mol Biol. 2012 Nov;47 (5) :718-26.